Alnylam Pharmaceuticals
ALNY
#1021
Rank
NZ$40.78 B
Marketcap
NZ$304.49
Share price
-1.36%
Change (1 day)
-63.55%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$9.61

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$9.81. In 2025 the company made an earnings per share (EPS) of NZ$3.65.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$9.61162.85%
2025NZ$3.65
2023NZ-$6.26-62%
2022NZ-$16.4829.03%
2021NZ-$12.77-3.36%
2020NZ-$13.22-8.48%
2019NZ-$14.447.67%
2018NZ-$13.4139.74%
2017NZ-$9.6012.94%
2016NZ-$8.5038.84%
2015NZ-$6.12-32.88%
2014NZ-$9.12259.44%
2013NZ-$2.54-31.25%
2012NZ-$3.69

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$11.81 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$3.38-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$74.35 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.67-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.30-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.16-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$1.12-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ-$5.91-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA